尽管目标价下调,该公司仍维持对其股票的买入评级。根据InvestingPro的分析,基于公平价值指标,该股票似乎被低估。此次调整反映了对Bicycle Therapeutics药物开发管线的重新评估。 该公司分析师指出,更新后的模型考虑了公司当前的管线状况。虽然InvestingPro数据显示该公司正在快速消耗现金,毛利率较低,但特别关注了正在开发多种用途的药物候选者zele。
A comprehensive evaluation of state efforts to improve cycling and expose its persistent challenges was released earlier this ...
The Ministry of Culture, Sports and Tourism announced the 60 best travel routes for bike riding around the country. The 60 ...
在其他近期新闻中,由于Zelenectide Pevedotin的有望数据,Needham和H.C. Wainwright维持了对Bicycle Therapeutics的买入评级,股票目标价分别为38.00美元和55.00美元。该药物在三阴性乳腺癌患者中显示出令人鼓舞的结果,尤其是在nectin-4基因扩增阳性的患者中。Leerink ...
Luke Hoffman, Iowa Bicycle Coalition director since October 2023, says he's just getting started on boosting safety, ...
At Ted's Bicycles, the spirit of Christmas starts in the summertime. The generational gem, open since 1971, has made it their ...
Hear from Iowa Bicycle Coalition executive director Luke Hoffman as he discusses the organization’s advocacy for safe ...
In the last three months, 8 analysts have published ratings on Bicycle Therapeutics BCYC, offering a diverse range of ...